{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:04Z","timestamp":1787772364124,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Vitamin D deficiency (VDD) is highly prevalent across the globe. Cholecalciferol (Vitamin D3) fails to attain sufficient serum concentrations of 25-hydroxyvitamin D (25(OH)D) in a significant proportion of supplemented individuals. Calcifediol (25-hydroxyvitamin D3) is less studied in healthy adults and its effects on 25(OH)D, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)2D) at higher doses are not well known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>The study was an open-label, interventional trial recruiting consecutive participants with VDD who were allocated to receive either 2 capsules (50 \u03bcg-group) or 1 capsule (25 \u03bcg-group) daily doses of calcifediol. Baseline assessment included clinicodemographic parameters, dietary calcium, calcemic (calcium, inorganic phosphate, albumin, alkaline phosphatase, urine spot calcium\/creatinine), and hormonal parameters (25(OH)D, PTH, and 1,25(OH)2D). Participants were followed up at 4 and 8 weeks with repeat assessments of calcemic and hormonal parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>There were 64 participants, 35 (50 \u03bcg-group) and 29 (25 \u03bcg-group), without any significant difference in any of the baseline parameters. 97.1% participants in the 50 \u03bcg-group (at 4 and 8 weeks) and 93.1% (at 4 weeks) and 96.5% (at 8 weeks) in the 25 \u03bcg-group attained 25(OH)D sufficiency (\u226530 ng\/ml) with calcifediol. The mean serum 25(OH)D was 84.0 \u00b1 27.7 ng\/ml in the 50 \u03bcg-group and 58.0 \u00b1 23.6 ng\/ml in the 25 \u03bcg-group group at 4 weeks, which later rose to 94.3 \u00b1 21.8 ng\/ml and 76.0 \u00b1 16.4 ng\/ml, respectively, at 8 weeks. PTH levels decreased in both groups at both time points. 1,25(OH)2D rose significantly in both groups at 4 and 8 weeks but was not significantly different between both groups. There was no case of incident hypercalcemia or symptomatic nephrolithiasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Calcifediol is a safe and efficacious alternative for oral Vitamin D supplementation in young adults. Increment in 25(OH)D levels is rapid and dose-dependent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_873_22","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:56:49Z","timestamp":1716479809000},"page":"286-292","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy, safety, and dose-response effects of calcifediol supplementation on 25-hydroxyvitamin D, parathyroid hormone, and 1,25-dihydroxyvitamin D levels in healthy adults"],"prefix":"10.4103","volume":"55","author":[{"given":"Liza","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Holick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shallu","family":"Singhmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetika","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman Kumar","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20240903","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jphotobiol.2014.07.018","article-title":"Influence of external, intrinsic and individual behaviour variables on serum 25 (OH) D in a German survey","volume":"140","author":"Richter","year":"2014","journal-title":"J Photochem Photobiol B: Biology"},{"key":"R3-2-20240903","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jsbmb.2011.05.009","article-title":"Association of vitamin D binding protein (VDBP) polymorphisms and serum 25 (OH) D concentrations in a sample of young Canadian adults of different ancestry","volume":"127","author":"Gozdzik","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R4-2-20240903","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.nut.2013.12.020","article-title":"Serum 25 (OH) D response to vitamin D3 supplementation: a meta-regression analysis","volume":"30","author":"Shab-Bidar","year":"2014","journal-title":"Nutrition"},{"key":"R5-2-20240903","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jsbmb.2012.12.003","article-title":"The effect of vitamin D supplementation on serum 25OHD in thin and obese women","volume":"136","author":"Gallagher","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R6-2-20240903","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1210\/jc.2011-3401","article-title":"Factors predicting vitamin D response variation in non-Hispanic white postmenopausal women","volume":"97","author":"Zhao","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-2-20240903","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2016-2930","article-title":"Effects of genetic and nongenetic factors on total and bioavailable 25 (OH) D responses to vitamin D supplementation","volume":"102","author":"Yao","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-2-20240903","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00198-009-1119-3","article-title":"Benefit-risk assessment of vitamin D supplementation","volume":"21","author":"Bischoff-Ferrari","year":"2010","journal-title":"Osteoporos Int"},{"key":"R9-2-20240903","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41430-020-0697-1","article-title":"Vitamin D supplementation: cholecalciferol, calcifediol, and calcitriol","volume":"74","author":"Vieth","year":"2020","journal-title":"Eur J Clin Nutr"},{"key":"R10-2-20240903","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3390\/nu14061168","article-title":"Calcifediol (25OH Vitamin D3) Deficiency: A Risk Factor from Early to Old Age","volume":"14","author":"Bouillon","year":"2022","journal-title":"Nutrients"},{"key":"R11-2-20240903","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41574-021-00593-z","article-title":"The health effects of vitamin D supplementation: Evidence from human studies","volume":"18","author":"Bouillon","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"R12-2-20240903","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/nu11071460","article-title":"Extra-skeletal effects of vitamin D","volume":"11","author":"Marino","year":"2019","journal-title":"Nutrients"},{"key":"R13-2-20240903","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jsbmb.2016.09.016","article-title":"Non-musculoskeletal benefits of vitamin D","volume":"175","author":"Wimalawansa","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R14-2-20240903","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bone.2013.10.014","article-title":"Pharmacokinetics of oral vitamin D3 and calcifediol","volume":"59","author":"Jetter","year":"2014","journal-title":"Bone"},{"key":"R17-2-20240903","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.clnu.2017.03.029","article-title":"Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: a randomized controlled trial in older adults","volume":"37","author":"Vaes","year":"2018","journal-title":"Clin Nutr"},{"key":"R18-2-20240903","doi-asserted-by":"crossref","first-page":"e10567","DOI":"10.1002\/jbm4.10567","article-title":"Vitamin D: bolus is bogus\u2014a narrative review","volume":"5","author":"Mazess","year":"2021","journal-title":"JBMR plus"},{"key":"R19-2-20240903","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/jbmr.551","article-title":"Oral supplementation with 25 (OH) D3 versus vitamin D3: effects on 25 (OH) D levels, lower extremity function, blood pressure, and markers of innate immunity","volume":"27","author":"Bischoff-Ferrari","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R20-2-20240903","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1515\/jpem-2012-0390","article-title":"Efficacy of vitamin D loading doses on serum 25-hydroxy vitamin D levels in school going adolescents: an open label non-randomized prospective trial","volume":"26","author":"Garg","year":"2013","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R21-2-20240903","doi-asserted-by":"crossref","first-page":"34","DOI":"10.6065\/apem.2019.24.1.34","article-title":"Reference range of random urinary calcium creatinine ratio in North Indian children and adolescents","volume":"24","author":"Marwaha","year":"2019","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"R22-2-20240903","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4236\/abc.2013.35049","article-title":"Determination of upper reference value of urinary calcium-creatinine ratio for the paediatric population in Burdwan district","volume":"3","author":"Pal","year":"2013","journal-title":"Adv Biol Chem"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_873_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:41:26Z","timestamp":1787769686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_873_22"}},"subtitle":["An open-label, interventional pilot study"],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_873_22","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}